Praet, Nicolas
Asante, Kwaku Poku
Bozonnat, Marie-Cecile
Akité, Elaine Jacqueline
Ansah, Patrick Odum
Baril, Laurence
Boahen, Owusu
Mendoza, Yolanda Guerra
Haine, Valerie
Kariuki, Simon
Lamy, Mathieu
Maleta, Kenneth
Mungwira, Randy
Ndeketa, Latif
Oduro, Abraham
Ogutu, Bernhards
Olewe, Fredrick
Oneko, Martina
Orsini, Mattéa
Roman, Francois
Bahmanyar, Edith Roset
Rosillon, Dominique
Schuerman, Lode
Sing’oei, Valentine
Terlouw, Dianne J.
Wéry, Stéphanie
Otieno, Walter
Pirçon, Jean-Yves
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
PATH
Article History
Received: 4 June 2021
Accepted: 29 March 2022
First Online: 25 April 2022
Change Date: 23 May 2022
Change Type: Update
Change Details: Following the original publication of this article, the graphic abstract has been updated with the DOI information 10.1186/s12936-022-04144-3, which had erreonously been omitted from the originally published version.
Declarations
:
: Not applicable.
: Not applicable.
: EJA, YGM, VH, FR, LS, SW and JYP are employees of the GSK group of companies. At the time of the study NP was an employee of the GSK group of companies and is now employed by Janssen Pharmaceutica NV. At the time of the study DR was an employee of the GSK group of companies and is now a freelance consultant at DESiRE-Consulting. NP, YGM, ML, FR, LS, DR and JYP hold shares in the GSK group of companies. ML is employee of Aixial on behalf of the GSK group of companies. MOr and MCB are employees of 4Clinics on behalf of the GSK group of companies. KPA, POA, OB, SK, KM, RM, LN, AO, BO, FO, MOn, VS, DJT and WO via their institutions, received grants from the GSK group of companies for the conduct of this study/work. KPA, OB, SK, WO, VS, KM and DJT via their institutions, received grants from the GSK group of companies for the conduct of studies outside the submitted work.